ICON wins multiple categories in 2020 CRO Leadership Awards third year in a row
09 Avril 2020 - 10:30AM
Business Wire
ICON recognised for specialised
services offering across product development lifecycle, winning
five awards overall
ICON plc, (NASDAQ: ICLR) a global provider of drug
development and commercialisation services to the pharmaceutical,
biotechnology and medical device industries, has won awards across
multiple categories in the annual CRO Leadership Awards.
This is the fourth year ICON has won awards in the CRO
Leadership Awards, having been successful in 2019, 2018 and
2015.
ICON received 2020 CRO Leadership Awards in five of the overall
six categories, each further divided into three groups – Big
Pharma, Small Pharma, and Overall. In two categories, ICON took
awards in all three groups.
Winning categories:
- Compatibility (Overall, Big Pharma)
- Expertise (Overall, Big Pharma, Small Pharma)
- Phase IV (Overall, Big Pharma)
- Quality (Overall, Big Pharma, Small Pharma)
- Reliability (Overall, Big Pharma)
Life Science Leader magazine and Clinical Leader once again
teamed up with Industry Standard Research (ISR) to determine the
award recipients. They assessed sixty contract research
organisations on over 20 performance metrics in ISR’s annual CRO
Quality Benchmarking survey.
Survey participants were recruited from pharma and biopharma
companies of all sizes and were screened for decision-making
influence related to working with contract research
organisations.
Dr Steve Cutler, Chief Executive Office, ICON plc, said: “We are
delighted to have been successful in five categories at the CRO
Leadership Awards for the third year in a row. These awards are a
testament to the dedication, hard work and expertise of ICON’s
scientific specialists and operational professionals. We are
particularly gratified that ICON’s expertise in the drug
development process has been recognised by both big and small
biopharma companies alike.”
A full list of ICON’s industry awards can be viewed at
www.iconplc.com/awards.
About ICON plc
ICON plc is a global provider of outsourced drug and device
development and commercialisation services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. The company specialises in the strategic
development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
currently operates from 97 locations in 40 countries and has
approximately 14,650 employees as at December 31, 2019. Further
information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200409005081/en/
ICON Media Gareth Arnold Weber Shandwick Telephone: (+44)
0207 418 0398 garnold@webershandwick.com
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024